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The aim of this investigation was to describe the outcomes of the adverse analytical 8 
findings in different Olympic sports. The data included were gathered from the WADA 9 
Anti-doping Rule Violations Reports (from 2013-2017).Weightlifting (78.1±9.4%,) 10 
wrestling (73.2±18.5%) and volleyball (68.3±18.7%) were the sports with the highest 11 
proportion of cases that ended in an anti-doping sanction. Gymnastics (45.1±10.1%), 12 
triathlon (32.6±11.9%) and shooting (29.9 ± 14.1%) were the sports with a higher 13 
frequency of cases that were not sanctioned due to medical reasons. Gymnastics (22.4± 14 
18.4%), boxing (23.2±16.0%) and taekwondo (17.3.1±16.4%) presented the highest 15 
proportion of cases that are still pending resolution. The proportion of cases that ended in 16 
no sanction was higher in fencing (26.2 ± 22.7%), skating (23.6 ± 35.1%) and tennis (18.6 17 
± 26.5%). These results indicate that the sanctions derived from ADRVs were not uniform 18 
in all sports disciplines. 19 
 20 
 21 




1. INTRODUCTION 24 
 25 
According to the World Anti-Doping Agency (WADA), the international and 26 
independent agency that harmonises anti-doping policies worldwide, a doping case is 27 
produced when an athlete or his/her support personnel breaks one or more of the anti-28 
doping rules set out in the World Anti-Doping Code [1]. Due to the diverse behaviours 29 
that can be considered as doping in modern sport, Article 2 of The Code includes 10 30 
circumstances that can be constitutive of an anti-doping rule violation. The presence of a 31 
prohibited substance in an athlete’s bodily specimens as well as the use of a prohibited 32 
method are the most common violations of The Code, but evading doping controls, 33 
Whereabout failures, tampering with a doping control, possession of a prohibited 34 
substance or a prohibited method, selling a banned substance to another athlete, or 35 
complicity and prohibited association are also considered anti-doping rule violations.   36 
If the violation is related to the presence of a prohibited substance, or its 37 
metabolites or marker, in a urine or blood sample, WADA-accredited laboratories 38 
endorse the presence of this substance by establishing an adverse analytical finding.  39 
However, there are other non-analytical anti-doping rule violations that can be certified 40 
by doping control officers (e.g., refusing to submit to a sample collection or a 41 
Whereabouts failure), or even police forces (e.g. possession or trafficking of a substance 42 
or a prohibited method). When an athlete commits a doping offence, the anti-doping 43 
organisations initiate legal actions against the potential offender to deliver a sanction or 44 
to investigate the circumstances that produced the violation of The Code. Interestingly, 45 
WADA is never involved in the management of the results of the doping control tests, 46 
instead the process is managed by the International Sports Federation in which the athlete 47 
is registered or by the national anti-doping organisation where the control was performed. 48 
Thus, although WADA monitors anti-doping activities worldwide and accredited 49 
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laboratories to guarantee that the presence of a substance in a bodily specimen is the result 50 
of the misuse of a doping substance, the international federations and the national anti-51 
doping organisations are responsible for presenting the cases against the doped athletes.  52 
Although the configuration of this anti-doping system has received criticism in the last 53 
years [2,3] the current anti-doping programme has effectively responded to the dynamic 54 
changes associated to doping [4]. However, there are still problems to be solved in the 55 
current anti-doping programme, such as the low deterrent effect of the punishment 56 
established for an anti-doping rule violation, the inclusion of substances on the banned 57 
list without proper scrutiny of their effects on physical performance, and the 58 
imperfections in the Therapeutic Use Exemption  protocol, among others [5,6]. 59 
Although each doping offence has its own legal process, the outcomes of an anti-60 
doping rule is common or all cases.  The case against the athlete can: (a) be closed with 61 
a sanction; (b) can be dropped if the athlete has a therapeutic use exemption; (c) can be 62 
closed at the results management level; (d) can be closed with the athlete being exonerated 63 
if the disciplinary proceedings concludes that the athlete committed no infraction of The 64 
Code. Still, some cases need several months or even years to be closed and are pending a 65 
final decision.  A recent analysis [7] has revealed that the prevalence of adverse analytical 66 
findings found by WADA-accredited laboratories has remained relatively stable at ~2% 67 
since the creation of WADA. However, the prevalence of adverse findings is not uniform 68 
across all sports disciplines. Individual sports such as cycling, weightlifting and boxing 69 
present a higher prevalence of adverse findings than team sports such as ice hockey, rugby 70 
and basketball [8]. Previous research has shown that more than 11% of the athletes who 71 
tested positive in a doping control test received no sanction, indicating that the specific 72 
circumstances of the case, or lack of available evidence, are important factors leading to 73 
a sanction [9]. However, to date, there is no information about how the adverse analytical 74 
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finding that constituted a potential doping case evolved until an outcome was obtained.  75 
Thus, the aim of this investigation was to describe the final consequences of adverse 76 
analytical findings in sport and to establish differences among sports disciplines.   77 
 78 
2. MATERIAL & METHODS 79 
The data included in this investigation have been gathered from the Anti-Doping 80 
Rule Violations Reports made available annually from 2013 to 2017 by WADA [10]. 81 
Only the outcomes of anti-doping rule violations associated to adverse analytical findings 82 
were analysed in this investigation. The anti-doping rule violations that resulted from 83 
non-analytical findings were discarded as it was unfeasible to determine its nature from 84 
the information contained in the Reports.  Hence, the current analysis presents the 85 
outcomes of adverse analytical findings in individual and team sports.  In 2013, it was the 86 
first time that WADA published the information about the number of adverse analytical 87 
findings per sport in a public report. Thus, the information for establishing anti-doping 88 
rule violations, respect to the total number of adverse analytical findings in each sport, 89 
has only been available in the last five Anti-Doping Rule Violations Reports (2013, 2014, 90 
2015, 2016 and 2017) and the present investigation represents an analysis of this period. 91 
To date, no Anti-Doping Rule Violations Report for 2018 has been released by WADA. 92 
These reports offered a complete analysis of all doping cases established during one year 93 
by compiling the legal decisions received by WADA. Although they contain information 94 
about the outcomes of analytical and non-analytical anti-doping rule violations, we have 95 
only used the information about the outcomes of adverse analytical findings because we 96 
aimed to associate these data on sanctioning per sport with the available data about the 97 
prevalence of adverse analytical findings per sport [8]. According to the reports, the 98 
outcomes of a doping case can be classified into five categories: 99 
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- Medical Reasons: Therapeutic Use Exemption granted to an athlete, which 100 
permits the presence of a prohibited substance and/or the use or attempted use, 101 
possession and/or administration or attempted administration of prohibited 102 
substances or methods for therapeutic purposes.  103 
- No Case to Answer: Cases closed at the results management level, excluding 104 
medical reasons, or cases outside of WADA’s jurisdiction. 105 
- No sanction: Cases in which the athlete was exonerated following the conclusion 106 
of disciplinary proceedings.  107 
- Pending: Cases that have not yet been finalised following either the conclusion of 108 
disciplinary proceedings or at the results management level. 109 
- Anti-doping rule violation (ADRV): Cases for which a final decision has been 110 
rendered and a sanction was imposed against the athlete.  111 
To fulfil the aim of this investigation, the analysis included the outcomes of adverse 112 
analytical findings of 25 Olympic sports (18 individual sports and 7 team sports). Sports 113 
with less than 1,400 samples analysed per year in all the years examined were excluded 114 
to guarantee that the distribution of adverse analytical finding outcomes was 115 
representative of each sport, as previously suggested [11].  In addition, for increase the 116 
statistical power of the analysis, we use the aggregate data of the 5 available reports. This 117 
analysis followed a similar pattern to a previous publication in which the differences in 118 
the frequency of adverse analytical findings  were established per sport [8]. 119 
2.1. Statistical analysis 120 
The data in the present study are presented as mean and standard deviation (SD) 121 
for each outcome ruled from 2013 to 2017.  Briefly, in each year, the proportion of 122 
outcomes were calculated for by dividing the number of each outcome (i.e., 123 
ADRV/Medical Reasons/Therapeutic Use Exemption/No Case to Answer/No sanction) 124 
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between the total number of outcomes.  Then, the data per year were averaged for the 5 125 
years under scrutiny.  The proportion of the outcomes of the adverse analytical findings 126 
was subsequently calculated in each sport by dividing the number of cases that ended in 127 
any specific outcome by the total number of adverse findings in the sport. The differences 128 
in distribution of outcomes among sports were tested with crosstabs and Chi Square test, 129 
including adjusted standardised residuals. Briefly, it was considered that a sport had a 130 
distribution of adverse analytical finding outcomes statistically different from the 131 
expected value when its distribution of adverse analytical finding outcomes was > or < 132 
the critical Z-score value (i.e., 1.96). As the Z-score is a measure of standard deviation, 133 
the sports that surpassed the above-mentioned threshold contained data that were 1.96 134 
standard deviations higher and lower than the mean value.  The significance level was set 135 
at p < 0.05. 136 
Table 1. Adverse analytical finding outcomes in Olympic sports from 2013 to 2017.  137 
Data are absolute values for each year.   138 
 139 











180740 1714 158†(9%) 
 
225*(13%) 78†(5%) 98†(6%) 1155†(67%) 
2014 186723 1439 157† (11%) 187*(13%) 102†(7%) 77†(5%) 916†(64%) 
        
2015 196579 1633 212(13%) 101†(6%) 147†(9%) 109†(7%) 1064†(65%) 
 
2015 193345 1926 215† (11%) 76†(4%) 510*(26%) 271(14%) 854†(44%) 
 
2017 205405 1575 152† (10%) 89† (6%) 103† (7%) 343*(22%) 886†(56%) 
 140 






3. RESULTS AND DISCUSSION 145 
Between 2013 and 2017, a total of 8,287 adverse findings were reported for the 146 
sports included in this investigation. During this period, the number of samples analysed 147 
increased, while the number of adverse findings per year has remained relatively constant 148 
(Table 1).  Specifically, the percentage of adverse findings in the reports included in this 149 
investigation has remained relatively stable below 1% (0.95% in 2013, 0.77% in 2014, 150 
0.83% in 2015, 1.00% in 2016 and 0.77 in 2017). These results coincide with previous 151 
research that included information on all the samples and findings reported by WADA 152 
for 13 years [7].  These data suggest a stable proportion of adverse analytical findings in 153 
the last years despite the increasing number of samples analysed by WADA-accredited 154 
laboratories. The current investigation is innovative because, in addition to the above 155 
conclusion, this is the first investigation to show that the evolution of the disciplinary 156 
outcomes of adverse analytical findings has also remained constant since 2013 (Table 1).  157 
Overall, the percentage of adverse findings that ended in ADRV was 58.8%.  The 158 
remaining cases are still pending (10.8%), have been closed due to medical reasons 159 
(10.8%) or because there was no case to answer (8.2%). From the total, 10.4% of the 160 
cases were closed without any sanction for the athlete.  The current analysis reflects that 161 
only a moderate proportion of doping cases initiated by anti-doping authorities ended in 162 
a sanction for the offender with question the deterrent effect of the anti-doping 163 
programme for athletes. To this, it is necessary to add that only ~2% of doping control 164 
tests report the presence of a banned substance [7,8] despite the prevalence of doping 165 
measured with other techniques such as questionnaires is between 14%–57% [12,13].  166 
Together, this information suggests the inefficacy of the anti-doping system to 167 
successfully prove that the presence of this substance is the result of a violation of The 168 
Code.   169 
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Some of the substances included in the banned list, such as β-2 agonists and 170 
glucocorticoids, might have a therapeutic use for athletes with a clinical condition and 171 
thus, some athletes are allowed to use prohibited medications in sport after their need is 172 
certified by a medical court (i.e., Therapeutic Use Exemption (TUE)) [14].  As a result of 173 
these exemptions, about 10% of adverse atypical findings are closed for medical reasons, 174 
a number higher than the frequency of Olympic athletes that compete under a TUE (0.9%) 175 
[15]. Thus, the TUE is an international standard with high utility to allow sports 176 
participation for those athletes with conditions that require the use of banned substances.  177 
However, the TUE is probably misused by healthy athletes as a ‘‘permissive’’ doping 178 
passport alongside the current antidoping methods [12,13].  The current system of TUEs 179 
allows athletes with clinical conditions to use some banned substances while competing 180 
in official events but there has been some argument against it [18].  The high number of 181 
TUEs conceded in particular sports, the high proportion of Olympic athletes that suffer 182 
from asthma [5], and the use of stimulants to treat athletes with attention-183 
deficit/hyperactivity disorder has also been questioned [19,20]. These concerns are 184 
aggravated in the light of the current data, because gymnastics, triathlon, shooting, 185 
aquatics, tennis, ice hockey, skiing, and cycling, with percentages varying from 45 to 186 
12%, presented a higher proportion of exoneration after adverse findings due to medical 187 








Figure 1. Mean frequency of adverse analytical findings outcomes between 2013 and 194 
2017 in individual sports195 
 196 
Figure 2. Mean frequency of adverse analytical findings outcomes between 2013 and 197 






























Interestingly, subtle changes have been present in the last few years when 200 
referring to the outcomes of the adverse analytical findings.  For example, the proportion 201 
of “no case to answer” has been reduced to half since 2015 (Table 1), likely due to the 202 
improvement in the management of the results in national anti-doping authorities and 203 
international federations.  In 2016, the proportion of adverse analytical findings that 204 
ended with athletes being exonerated of culpability increased to 26% while this outcome 205 
did not exceed 9% in the remaining years.  Likely, this significant increase in “no 206 
sanction” cases in 2016 is related to the prohibition of meldonium which was added to 207 
the 2016 Prohibited List [21]. Many of the athletes who were sanctioned for having 208 
committed an anti-doping rule violation due to the use of meldonium denied that they 209 
consciously breached anti-doping regulations.  In fact, a previous report suggested that 210 






























violate the regulations [9]. In any case, The Code clearly certifies that, although the 212 
athlete has the right to a hearing after a doping case has been initiated, the anti-doping 213 
authority does not need to demonstrate intent, conscious use, fault or negligence on the 214 
athlete’s part.  215 
Regarding adverse analytical findings that ended in "no sanction", the distribution 216 
was similar in individual (12.2 ± 0.1%) and team sports (10.8 ± 0.1%) during the 217 
examined period. These findings coincide with previous research that reported that 11% 218 
of athletes who tested ‘positive’ after a doping control received a sanction of zero months 219 
ineligibility [9]. This means that around 11% of athletes notified with an adverse 220 
analytical finding were either regarded as having no fault or negligence because of the 221 
circumstances of the case, or the available evidence was insufficient to justify a ban.  222 
Fencing, skating, football, tennis, aquatics, canoe/kayaking and athletics, with 223 
proportions between 26% and 12%, presented higher than expected proportions of cases 224 
that ended with no sanction. Despite reporting the percentage of doping cases that do not 225 
end with a sanction, WADA does not indicate why these cases were closed with no 226 
sanction.   227 
A total of 633,884 samples were analysed from the individual sports selected for 228 
this investigation between 2013 and 2017 with an overall frequency of adverse findings 229 
of 0.9 ± 0.5%. Figure 1 depicts the distribution of the outcomes of the adverse analytical 230 
findings reported in each sport. In weightlifting, wrestling and athletics, the proportion of 231 
cases that ended in ADRV was higher than expected (p < 0.05). In contrast, the proportion 232 
of cases closed due to medical reasons was higher than expected in gymnastics, triathlon, 233 
shooting, aquatics, tennis, skiing, and cycling (p < 0.05). In skiing, biathlon and cycling, 234 
the outcomes classified as "no case to answer" were higher than expected (p < 0.05).  The 235 
adverse analytical findings that ended in "no sanction" were higher than expected in 236 
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fencing, skating, tennis, aquatics, canoe/kayaking, and athletics (p < 0.05).  Finally, the 237 
proportion of cases that are still "pending" resolution were higher than expected in boxing 238 
and gymnastics (p < 0.05). In team sports, the number of samples analysed was 291,587 239 
while the frequency of adverse findings was lower than in individual sports (overall, 0.7 240 
± 0.3%; p < 0.05). The distribution of the outcomes of the adverse analytical findings per 241 
sport are presented in Figure 2.  Volleyball and rugby were the sports with a higher 242 
proportion than expected of adverse analytical findings that ended in ADRV (p < 0.05). 243 
The proportion of cases closed due to medical reasons and the cases classified as "no case 244 
to answer" was higher than expected in ice hockey (p < 0.05).  Adverse analytical findings 245 
that ended in "no sanction" or the ones that are still pending a final decision were higher 246 
than expected in football (p < 0.05).  These data indicate that the outcomes of the doping 247 
cases initiated by the anti-doping authorities present some sport-specific differences.  In 248 
some sports, a higher proportion of cases ended in ADRV which may indicate that 249 
athletes in these sports were using substances and methods in a context that facilitated 250 
detection first and sanction later (i.e., in terms of type of substance, dose administered, 251 
method of administration).  In this regard, the highest frequency of ADRVs were within 252 
the sports with a high proportion of adverse analytical findings associated with anabolic 253 
agents [11]. As this is an innovative finding of this investigation, further studies should 254 
be aimed at determining why some sports receive a higher proportion of sanctions.   255 
The current study has some limitations that should be discussed to correctly 256 
understand its outcomes. First, the 2016 ADRV Report covered decisions received by 257 
WADA until 31 December 2017, whereas in previous reports the period of decisions was 258 
longer.  However, the 2017 ADRV Report covered decisions received by WADA before 259 
31 May 2019. The increase in the load of adverse findings could have led to 260 
corresponding delays in finalising decisions.  In addition, unequivocally determining an 261 
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anti-doping rule violation in anti-doping cases has become more and more complex due 262 
to the meticulous processes necessary to certify the correct implementation of the protocol  263 
for the obtaining of anti-doping samples, the intricate laboratory methods employed to 264 
detect substances and the existence of national anti-doping regulations that tackle the 265 
determination of a final sanction, which often affects their duration. All of these causes 266 
might have affected the progressively higher proportion of pending cases reported in 267 
Table 1.  Secondly, this analysis does not include sanctions of non-analytical anti-doping 268 
rule infractions. Additionally, the current investigation will never be totally complete due 269 
to the 10-year window permitted for retrospective analysis. The use of retrospective 270 
testing is a deterrent strategy against doping [1] which allows anti-doping authorities to 271 
analyse an athlete’s sample retrospectively for 10 years to look for a possible violation of 272 
The Code.  To date, there is a gap between WADA becoming aware of a new 273 
performance-enhancing substance and the development of a valid and reliable laboratory 274 
test.  Because of this, the International Olympic Committee has allowed retrospective 275 
testing since the Athens Olympics in 2004; where 5 athletes were caught retrospectively, 276 
while 90% of ADRVs in 2008 and 87% in 2012 were granted from retrospective testing 277 
[22]. In addition, as mentioned in other research [9], there are various reasons why a 278 
sanction could be mitigated according to the anti-doping rules, such as collaboration with 279 
anti-doping organisations to detect other athletes or an athlete’s support person who are 280 
committing anti-doping rule violations.  281 
 282 
4. CONCLUSIONS 283 
In conclusion, the analysis of the WADA Anti-Doping Rule Violations Reports 284 
suggests that most of the adverse analytical findings detected by WADA-accredited 285 
laboratories ended with the certification that an antidoping rule violation had occurred.  286 
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However, the conversion of adverse analytical findings into violations of The Code was 287 
not uniform in all sports disciplines. The current analysis reveals that some sports had a 288 
higher proportion of anti-doping rule violations for a given number of adverse findings 289 
than others.  290 
5. FUTURE PERSPECTIVE 291 
Because WADA is not involved in the first steps of the management of the results of 292 
the doping control tests, the analysis presented here recommends national anti-doping 293 
authorities and international federations to use the information about the doping 294 
characteristics of each sport (banned substances more commonly found in doping control 295 
tests, proportion of medical exemptions, schedule of international events, etc.) to increase 296 
the efficacy of the deterrent and punitive policies. However, WADA should perform a 297 
further examination to understand why some adverse analytical findings do not end in a 298 
sanction.  Finally, WADA should reconsider the international standard that regulates the 299 
concession of TUEs, particularly in some sports, due to the abnormal number of doping 300 
cases exonerated for medical reasons.   301 
  302 
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6. EXCUTIVE SUMMARY 
Background 
• The use of prohibited substances and methods is the most common infraction of the anti-doping rules.  However, other behaviours such 
as evading doping controls, tampering with a doping control or possession of a prohibited substance are also catalogued as anti-doping 
rule violations.  
• While there is ample information about the prevalence in the use of banned substances, there is no information about the consequences 
of adverse analytical findings in sport. 
Results 
• Weightlifting, wrestling and volleyball were the sports with the highest proportion of cases that ended in an anti-doping sanction. 
• Gymnastics, triathlon and shooting were the sports with a higher frequency of cases that were not sanctioned due to medical reasons.  
• Gymnastics, boxing and taekwondo presented a higher proportion of cases that are still pending resolution.  
• The proportion of cases that ended in no sanction was higher in fencing, skating, and tennis. 
Conclusion 
• The outcomes of an adverse analytical finding might differ among disciplines because of the characteristics of the sport and differences 
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